← Human Trials & Peer-Reviewed Studies
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Plain-language guide to NCT07866066: phase 3 randomized trial of Semaglutide and MariTide (Maridebart Cafraglutide), 1300 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07866066
- Phase
- phase 3
- Status
- not yet recruiting
- Start
- 2026-11-02
- Completion (planned or actual)
- 2028-09-04
- Participants
- 1300 (estimated)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Diabetes Mellitus, Type 2
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 3 trial, researchers set out to test Semaglutide and MariTide (Maridebart Cafraglutide).
It had two arms (groups): Maridebart cafraglutide (experimental) and Semaglutide (active comparator).
The registry classes the interventions as drug.
Who Took Part
1300 planned participants were the target.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Body mass index (BMI) ≥ 25 kilograms per meter squared (kg/m\^2) at screening.
The full record lists 3 inclusion and 9 exclusion criteria; among the exclusions: participants who are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema; participants who have a diagnosis of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy; history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
How the Study Was Run
Design: randomized, parallel-group and open-label.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
The Semaglutide group and the comparison group ran side by side rather than switching.
Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.
It started in 2026-11-02 with completion listed for 2028-09-04.
Its stated primary purpose is treatment.
What Was Measured
It also tracked 13 secondary outcomes, for example Percent Change from Baseline in Body Weight at Week 68, Change from Baseline in Fasting Plasma Glucose at Week 68, Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants Experiencing ≥ Level 2 American Diabetes Association (ADA) Defined Hypoglycemic Episodes and Plasma Concentration of Maridebart Cafraglutide at Week 68.
What This Means in Plain Language
Put simply, this is a phase 3, randomized trial of Semaglutide and MariTide (Maridebart Cafraglutide) in 1300 people.
With 1300 participants it is a large trial for this field.
Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page and the MariTide (Maridebart Cafraglutide) compound page, all human trials.
Our Notes on the Compounds
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
MariTide (Maridebart Cafraglutide): Amgen's once-monthly antibody-peptide conjugate that blocks GIP receptors and activates GLP-1 receptors, in phase 3 obesity trials. News and evidence page only.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.